Cancer shares striking similarities with fetal development.

D.F. Flavin, M.D., M.S.

Cancer shares striking similarities with fetal development. The major enzymes, receptors and growth hormones present in cancer are also seen in early fetal stages.

Research suggests that cancer cells react to damage and toxicity by regressing to a metabolic state akin to fetal cells, a survival mechanism that allows them to continue proliferating. These cells rely on genes that were highly active during the first trimester of human development. When genetic mutations disable inhibitors typically expressed in later fetal development—genes responsible for cell differentiation—cancer growth continues unchecked (Flavin, 2023).

A promising frontier in cancer research involves teratogens—chemicals and plant-derived compounds known to cause mutations and fetal abnormalities. These substances are now being studied for their ability to inhibit cancer pathways, particularly in cancer stem cells.

One such pathway, the hedgehog signaling pathway, plays a crucial role in tumor development and tissue regeneration (Taipale & Beachy, 2001). Because teratogens are lethal to fetal cells but not to maternal cells, they may selectively target cancer stem cells while sparing the patient. Early trials suggest these compounds exhibit minimal side effects while exerting a direct inhibitory effect on cancer growth (Rudin et al., 2009).

This emerging field of research offers exciting possibilities for novel cancer therapies and potential cures.

Dr. Flavin is the Medical Director for the Foundation for Collaborative Medicine and Research, a Research Institute in Greenwich, CT. www.collmed.org

References

• Flavin, D.F. (2023). Cancer Metabolism and Fetal Gene Expression. Foundation for Collaborative Medicine.
• Taipale, J., & Beachy, P.A. (2001). The hedgehog and Wnt signaling pathways in cancer. Nature, 411(6835), 349–354.
• Rudin, C.M., Hann, C.L., Laterra, J., Yauch, R.L., et al. (2009). Treatment of medulloblastoma with hedgehog pathway inhibitors. New England Journal of Medicine, 361(12), 1173-1181.